Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma

Autores
Kamper, Peter; Lugvigsen, Maja; Bendix, Knud; Hamilton Dutoit, Stephen; Rabinovich, Gabriel Adrian; Boe Møller, Michael; Nyengaard, Jens; Honoré, Bent; d'Amore, Franceso
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHL cases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (≤ 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease.
Fil: Kamper, Peter. Aarhus University Hospital. Department of Hematology; Dinamarca
Fil: Lugvigsen, Maja. University Aarhus; Dinamarca
Fil: Bendix, Knud. Aarhus University Hospital. Institute of Pathology; Dinamarca
Fil: Hamilton Dutoit, Stephen. Aarhus University Hospital. Institute of Pathology; Dinamarca
Fil: Rabinovich, Gabriel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina
Fil: Boe Møller, Michael. Odense University Hospital. Department of Pathology; Dinamarca
Fil: Nyengaard, Jens. Aarhus University Hospital. Center for Stochastic Geometry and Advanced Bioimaging. Stereology & Electron Microscopy Laboratory; Dinamarca
Fil: Honoré, Bent. University Aarhus; Dinamarca
Fil: d'Amore, Franceso. Aarhus University Hospital. Department of Hematology; Dinamarca
Materia
Hodgkin Lymphoma
Biomarker
Galectin-1
Proteomics
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/10664
Acceder
id CONICETDig_5c339a49e9f2cb6604cd9b93e726cf38
oai_identifier_str oai:ri.conicet.gov.ar:11336/10664
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphomaKamper, PeterLugvigsen, MajaBendix, KnudHamilton Dutoit, StephenRabinovich, Gabriel AdrianBoe Møller, MichaelNyengaard, JensHonoré, Bentd'Amore, FrancesoHodgkin LymphomaBiomarkerGalectin-1Proteomicshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHL cases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (≤ 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease.Fil: Kamper, Peter. Aarhus University Hospital. Department of Hematology; DinamarcaFil: Lugvigsen, Maja. University Aarhus; DinamarcaFil: Bendix, Knud. Aarhus University Hospital. Institute of Pathology; DinamarcaFil: Hamilton Dutoit, Stephen. Aarhus University Hospital. Institute of Pathology; DinamarcaFil: Rabinovich, Gabriel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); ArgentinaFil: Boe Møller, Michael. Odense University Hospital. Department of Pathology; DinamarcaFil: Nyengaard, Jens. Aarhus University Hospital. Center for Stochastic Geometry and Advanced Bioimaging. Stereology & Electron Microscopy Laboratory; DinamarcaFil: Honoré, Bent. University Aarhus; DinamarcaFil: d'Amore, Franceso. Aarhus University Hospital. Department of Hematology; DinamarcaAmerican Society Of Hematology2011-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/10664Kamper, Peter; Lugvigsen, Maja; Bendix, Knud; Hamilton Dutoit, Stephen; Rabinovich, Gabriel Adrian; et al.; Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma; American Society Of Hematology; Blood, The Journal Of The American Society Of Hematology - Print; 117; 24; 6-2011; 6638-66490006-49711528-0020enginfo:eu-repo/semantics/altIdentifier/url/http://www.bloodjournal.org/content/117/24/6638info:eu-repo/semantics/altIdentifier/doi/10.1182/blood-2010-12-327346info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:47:21Zoai:ri.conicet.gov.ar:11336/10664instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:47:21.303CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
title Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
spellingShingle Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
Kamper, Peter
Hodgkin Lymphoma
Biomarker
Galectin-1
Proteomics
title_short Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
title_full Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
title_fullStr Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
title_full_unstemmed Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
title_sort Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma
dc.creator.none.fl_str_mv Kamper, Peter
Lugvigsen, Maja
Bendix, Knud
Hamilton Dutoit, Stephen
Rabinovich, Gabriel Adrian
Boe Møller, Michael
Nyengaard, Jens
Honoré, Bent
d'Amore, Franceso
author Kamper, Peter
author_facet Kamper, Peter
Lugvigsen, Maja
Bendix, Knud
Hamilton Dutoit, Stephen
Rabinovich, Gabriel Adrian
Boe Møller, Michael
Nyengaard, Jens
Honoré, Bent
d'Amore, Franceso
author_role author
author2 Lugvigsen, Maja
Bendix, Knud
Hamilton Dutoit, Stephen
Rabinovich, Gabriel Adrian
Boe Møller, Michael
Nyengaard, Jens
Honoré, Bent
d'Amore, Franceso
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hodgkin Lymphoma
Biomarker
Galectin-1
Proteomics
topic Hodgkin Lymphoma
Biomarker
Galectin-1
Proteomics
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHL cases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (≤ 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease.
Fil: Kamper, Peter. Aarhus University Hospital. Department of Hematology; Dinamarca
Fil: Lugvigsen, Maja. University Aarhus; Dinamarca
Fil: Bendix, Knud. Aarhus University Hospital. Institute of Pathology; Dinamarca
Fil: Hamilton Dutoit, Stephen. Aarhus University Hospital. Institute of Pathology; Dinamarca
Fil: Rabinovich, Gabriel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina
Fil: Boe Møller, Michael. Odense University Hospital. Department of Pathology; Dinamarca
Fil: Nyengaard, Jens. Aarhus University Hospital. Center for Stochastic Geometry and Advanced Bioimaging. Stereology & Electron Microscopy Laboratory; Dinamarca
Fil: Honoré, Bent. University Aarhus; Dinamarca
Fil: d'Amore, Franceso. Aarhus University Hospital. Department of Hematology; Dinamarca
description Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHL cases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (≤ 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease.
publishDate 2011
dc.date.none.fl_str_mv 2011-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/10664
Kamper, Peter; Lugvigsen, Maja; Bendix, Knud; Hamilton Dutoit, Stephen; Rabinovich, Gabriel Adrian; et al.; Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma; American Society Of Hematology; Blood, The Journal Of The American Society Of Hematology - Print; 117; 24; 6-2011; 6638-6649
0006-4971
1528-0020
url http://hdl.handle.net/11336/10664
identifier_str_mv Kamper, Peter; Lugvigsen, Maja; Bendix, Knud; Hamilton Dutoit, Stephen; Rabinovich, Gabriel Adrian; et al.; Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma; American Society Of Hematology; Blood, The Journal Of The American Society Of Hematology - Print; 117; 24; 6-2011; 6638-6649
0006-4971
1528-0020
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.bloodjournal.org/content/117/24/6638
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood-2010-12-327346
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society Of Hematology
publisher.none.fl_str_mv American Society Of Hematology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268853112930304
score 13.13397

Publicaciones similares